Cell and Gene Therapy Global Market Report 2024 - Gene therapy involves delivering genetic material, typically through a carrier or vector, with the gene being taken up by the appropriate body cells. Cell therapy, on the other hand, entails introducing c
The global cell and gene therapy manufacturing market size was valued at USD 7.28 billion in 2022 and is expected to witness a compound annual growth rate (CAGR) of 26.6% from 2023 to 2030
North America: High economic status and high expenditure on healthcare services drive the cell and gene therapy market in North America. National Health Institutes, industries, academic institutes, and hospitals are the significant contributors of sponsorship and financial funding for cell and gene...
According to the latest research by nova one advisor, the global cell and gene therapy market size was valued at USD 18.13 billion in 2023 and is anticipated to reach around USD 97.33 billion by 2033, growing at a CAGR of 18.3% from 2024 to 2033. Request PDF Sample Copy ...
The global cell and gene therapy manufacturing services market reached $4.9 billion in 2022, should reach $5.7 billion by 2023 and $11.8 billion by 2028 with a compound annual growth rate (CAGR) of 15.7% during the forecast period of 2023-2028. ...
BCC Research Market Analyst says global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a CAGR of 10.8%.
Following acquisitions and in-house developments, IMA has evolved into a one-stop-shop supplier, says Thomas Fricke, Commercial Director o IMA Pharma. At Achema IMA presents a developement opening up the cell- and gene therapy market. Thomas Fricke, Commercial Direc...
Cell therapy and gene therapy aims to treat, prevent, or potentially cure diseases. It has the potential to alleviate the underlying cause of genetic diseases and acquired diseases. Projected to expand at a CAGR of 28.2% from 2022 to 2028, the global ...
Map your CGT strategy—and success—around a matrix of excellence that factors in market entry, regulation, portfolio and IP, and commercial viability. Introduction ThisMarch, gene therapy made a significant breakthrough—scientists at the Oregon Health & Science University in Portland,...
Choose Lonza as your CDMO partner for your cell and gene therapy development and manufacturing needs. Contact us today to learn more about our services and how we can help bring your therapy to market faster. Our state-of-the-art facilities and high quality control processes also ensure that...